NCT07000292View on ClinicalTrials.gov

MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

May 20, 2026

Study Completion Date

February 20, 2027

Conditions
Lupus Nephritis (LN)ANCA-Associated Glomerulonephritis
Interventions
DRUG

Injection of MSC303

Dose Group 1: D1, D8, D15, and D36 were respectively given 1, 5, 15, and 15 mg of MSC303 for injection; The second dose group: D1, D8, D15 and D36 were respectively given for injection MSC303 1, 5, 20, 20 mg.

Trial Locations (1)

200003

Shanghai Changzheng Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Changzheng Hospital

OTHER

NCT07000292 - MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease. | Biotech Hunter | Biotech Hunter